I tend to think the latter but I certainly understand any frustration holders may have, I am super disappointed with the execution of commercializing PromarkerD. Lack of news on the US partnership is worrisome coupled with a poor performing quarter makes it hard to justify the Market cap above 30.
But the potential with Jannsen and forever imminent commercialization of PromarkerD can really set this thing off.
Regarding China - I remember a couple years ago on an investor call Richard mentioned a number of challenges with penetrating into China, if I recall correctly it was something to do with the standards on how the kits were made - perhaps Rad or the other LT investors on here can clarify.
But personally I am not fussed about China, the prize is the US - with all the evidence from the PD trials and so forth now baked into the American diabetes literature, PD is recognized which should help catapult it as a gold standard in testing for CKD.
Let's see what Richard gives us in this upcoming "Significant" update.
Cheers
PIQ Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
haha
(20min delay)